Multiple risk factor intervention in chronic kidney disease: Management of cardiac disease in chronic kidney disease patients

Medical Clinics of North America

Volumn 89, Issue 3, 2005, Pages 511-523

  Curtis, Bryan M ^a   Levin, Adeera ^b,c   Parfrey, Patrick S ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN;

ANEMIA; ANGINA PECTORIS; ARTERY DISEASE; ARTERY THROMBOSIS; ATHEROSCLEROSIS; BLEEDING; CALCIUM METABOLISM; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; ELECTROLYTE DISTURBANCE; HEALTH CARE; HEALTH CARE COST; HEART DISEASE; HEART FAILURE; HEMODIALYSIS; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; PHOSPHATE METABOLISM; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SMOKING; TREATMENT CONTRAINDICATION; UREMIA;

EID: 14744286455     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2004.12.002     Document Type: Review

References (92)

1. B.A. Kiberd, and C.M. Clase Cumulative risk for developing end-stage renal disease in the US population J Am Soc Nephrol 13 2002 1635 1644
2. B.F. Culleton, M.G. Larson, and P.W.F. Wilson Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency Kidney Int 56 1999 2214 2219
3. R.N. Foley, P.S. Parfrey, and M.J. Sarnak Epidemiology of cardiovascular disease in chronic renal disease J Am Soc Nephrol 9 12 Suppl 1998 S16 S23
4. R. Goeree, J. Manalich, and P. Grootendorst Cost analysis of dialysis treatments for end-stage renal disease (ESRD) Clin Invest Med 18 1995 455 464
5. H. Lee, B. Manns, and K. Taub Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access Am J Kidney Dis 40 2002 611 622
6. US Renal Data System USRDS 2003 annual data report: atlas of end-stage renal disease in the United States 2003 National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Bethesda
7. A.R. Nissenson, B.J. Periera, and A.J. Collins Prevalence and characteristics of individuals with chronic kidney disease in a large health maintenance organization Am J Kidney Dis 37 2001 1177 1183
8. C.M. Clase, A.X. Garg, and B.A. Kiberd Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Survey (NHANES III) J Am Soc Nephrol 13 2002 1338 1349
9. C.-Y. Hsu, G.M. Chertow, and G.C. Curhan Methodological issues in studying the epidemiology of mild to moderate chronic renal insufficiency Kidney Int 61 2002 1567 1576
10. B.F. Culleton, M.G. Larson, and J.C. Evans Prevalence and correlates of elevated serum creatinine levels Arch Intern Med 159 1999 1785 1790
11. J. Coresh, G.L. Wei, and G. McQuillan Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the Third National Health and Nutrition Examination Survey (1988-1994) Arch Intern Med 161 2001 1207 1216
12. J. Coresh, B.C. Astor, and T. Greene Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey Am J Kidney Dis 41 2003 1 12
13. S. Klahr, A.S. Levey, and G.J. Beck The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease N Engl J Med 330 1994 877 884
14. L.G. Hunsicker, S. Adler, and A. Caggiula Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study Kidney Int 51 1997 1908 1919
15. M.J. Landray, J. Thambyrajah, and F.J. McGlynn Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment Am J Kidney Dis 38 2001 537 546
16. M.J. Sarnak, B.E. Coronado, and T. Greene Cardiovascular disease risk factors in chronic renal insufficiency Clin Nephrol 57 2002 327 335
17. W.K. Bolton, and A.S. Kliger Chronic renal insufficiency: current understandings and their implications Am J Kidney Dis 36 6 Suppl 3 2000 S4 S12
18. M.J. Sarnak, and A.S. Levey Cardiovascular disease and chronic renal disease: a new paradigm Am J Kidney Dis 36 4 Suppl 1 2000 S117 S131
19. P. Muntner, H. Jiang, and L. Hamm Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States J Am Soc Nephrol 13 2002 745 753
20. A.X. Garg, W.F. Clark, and B. Haynes Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I Kidney Int 61 2002 1486 1494
21. 2001 Report, volume 1: dialysis and renal transplantation. Canadian Organ Replacement Register 2001 Canadian Institute for Health Information Ottawa, Ontario
22. B.J. Barrett, P.S. Parfrey, and J. Morgan Prediction of early death in end-stage renal disease patients starting dialysis Am J Kidney Dis 29 1997 214 222
23. P.S. Parfrey, R.N. Foley, and J.D. Harnett Outcome and risk factors for left ventricular disorders in chronic uremia Nephrol Dial Transplant 11 1996 1277 1285
24. A. Levin, J. Singer, and C.R. Thompson Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention Am J Kidney Dis 27 1996 347 354
25. R.N. Foley, P.S. Parfrey, and J.D. Harnett Clinical and echocardiographic disease in patients starting end-stage renal disease therapy Kidney Int 47 1995 186 192
26. G. London, and P.S. Parfrey Cardiac disease in chronic uremia: pathogenesis Adv Ren Replace Ther 4 1997 194 211
27. C. Rigatto, P. Parfrey, and R. Foley Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease J Am Soc Nephrol 13 2002 1084 1090
28. R.N. Foley, P.S. Parfrey, and G.M. Kent Long-term evolution of cardiomyopathy in dialysis patients Kidney Int 54 1998 1720 1725
29. A. Levin, C.R. Thompson, and J. Ethier Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin Am J Kidney Dis 34 1999 125 134
30. C. Rigatto, R.N. Foley, and G.M. Kent Long-term changes in left ventricular hypertrophy after renal transplantation Transplantation 27 4 2000 570 575
31. P.S. Parfrey Pathogenesis of cardiac disease in dialysis patients Semin Dial 12 2 1999 62 68
32. G.M. London, A.P. Guerin, and S.J. Marchais Hemodynamic overload in end-stage renal disease patients Semin Dial 12 1999 77 83
33. L. Hansson, A. Zanchetti, and S.G. Carruthers Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial Lancet 351 1998 1755 1762
34. R.O. Estacio, N. Gifford, and B.W. Jeffers Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes Diabetes Care 23 Suppl 2 2000 B54 B64
35. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 BMJ 317 1998 703 713
36. PROGRESS Collaborative Group Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack Lancet 358 2001 1033 1041
37. A.V. Chobanian, G.L. Bakris, and H.R. Black The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure JAMA 289 2003 2560 2571
38. G. Bakris, M. Williams, and L. Dworkin Preserving renal function in adults with hypertension and diabetes: a consensus approach Am J Kidney Dis 36 2000 646 661
39. R.D. Toto, H.C. Mithell, and R.D. Smith Strict blood pressure control and progression of renal disease in hypertensive nephrosclerosis Kidney Int 48 1995 851 859
40. J.M. Lazarus, J.J. Bourgoignie, and V.M. Buckalew Achievement and safety of a low blood pressure goal in chronic renal disease Hypertension 29 1997 641 650
41. M.R. Weir, and L.D. Dworkin Antihypertensive drugs, dietary salt, and renal protection: how low should you go and with which therapy? Am J Kidney Dis 32 1998 1 22
42. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N Engl J Med 325 1991 293 302
43. J.F.E. Mann, H.C. Gerstein, and J. Pogue Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial Ann Intern Med 134 2001 629 636
44. E.J. Lewis, L.G. Hunsicker, and R.P. Bain The effect of angiotension-converting-enzyme inhibition on diabetic nephropathy N Engl J Med 329 20 1993 1456 1462
45. M. Ravid, H. Savin, and I. Jutrin Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients Ann Intern Med 118 1993 577 581
46. T. Philipp, M. Anlauf, and A. Distler Randomized, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study BMJ 15 1997 154 159
47. T.H. Jafar, C.H. Schmid, and M. Landa Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data Ann Intern Med 135 2001 73 87
48. The SOLVD Investigators Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions N Engl J Med 327 1992 685 691
49. M.A. Pfeffer, E. Braunwald, and L.A. Moyé Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 327 1992 669 677
50. B.M. Brenner, M.E. Cooper, and D. deZeeuw Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 2001 861 869
51. E.J. Lewis, L.G. Hunsicker, and W.R. Clarke Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 2001 851 860
52. S.D. Fihn, S.V. Williams, and J. Daley American College of Cardiology, American Heart Association, American College of Physicians-American Society of Internal Medicine. Guidelines for the management of patients with chronic stable angina: treatment Ann Intern Med 135 2001 616 632
53. K. Bhagat, and J.G. Hakim Why beta blockers should be used in heart failure Cent Afr J Med 45 1999 187 189
54. E. Lonn, and R. McKelvie Drug treatment in heart failure BMJ 320 2000 1188 1192
55. T.J. Ryan, J.L. Anderson, and E.M. Antman ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction) J Am Coll Cardiol 28 1996 1328 1428
56. F.A. McAlister, J. Ezekowitz, and M. Tonelli Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study Circulation 109 2004 1004 1009
57. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
58. J. Hirsh Guidelines for antithrombotic therapy 4th edition 2001 BC Decker Hamilton, Ontario
59. A. Levin, O. Djurdjev, and B. Barrett Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter Am J Kidney Dis 38 2001 1398 1407
60. G.M. London, B. Pannier, and S.J. Marchais Calcification of the aortic valve in the dialyzed patient J Am Soc Nephrol 11 2000 778 783
61. J.M. McLenachan, E. Henderson, and H.J. Dargie A possible mechanism of sudden death in hypertensive left ventricular hypertrophy J Hypertens 5 Suppl 5 1997 630
62. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Retinopathy and nephropathy in patients with type I diabetes four years after a trial of intensive therapy N Engl J Med 342 2000 381 389
63. Prospective Diabetes Study UK, and (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
64. Prospective Diabetes Study UK. (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 1998 854 865
65. R.N. Foley, C.A. Herzog, and A.J. Collins Smoking and cardiovascular outcomes in dialysis patients: the United States Renal Data System Wave 2 study Kidney Int 63 2003 1462 1467
66. K. Wilson, N. Gibson, and A. Willan Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies Arch Intern Med 160 2000 939 944
67. M. Regalado, S. Yang, and D.E. Wesson Cigarette smoking is associated with augmented progression of renal insufficiency in severe essential hypertension Am J Kidney Dis 35 2000 687 694
68. S.R. Orth, A. Stockmann, and C. Conradt Smoking as a risk factor for end-stage renal failure in men with primary renal disease Kidney Int 54 1998 926 931
69. S.R. Orth Smoking and the kidney J Am Soc Nephrol 13 2002 1663 1672
70. I. Mulder, M. Tijhuis, and H.A. Smit Smoking cessation and quality of life: the effect of amount of smoking and time since quitting Prev Med 33 2001 653 660
71. G.F. Feeney, A. McPherson, and J.P. Connor Randomized controlled trial of two cigarette quit programmes in coronary care patients after acute myocardial infarction Intern Med J 31 2001 470 475
72. S.G. Rostand, and T.B. Drueke Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure Kidney Int 56 1999 383 392
73. G.A. Block, T.E. Hulbert-Shearon, and N.W. Levin Association of serum phosphorus and calcium × phosphate product with mortality risk on chronic hemodialysis: a national study Am J Kidney Dis 31 1998 607 617
74. National Kidney Foundation K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease Am J Kidney Dis 42 Suppl 3 2003 S1 S202
75. M. Tonelli, L. Moye, and F.M. Sacks Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency Ann Intern Med 138 2003 98 104
76. R. Collins, J. Armitage, and S. Parish MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 361 2003 2005 2016
77. R. Moore Therapeutic considerations for the use of statin therapy in chronic renal disease Nephron Clin Pract 95 2003 c107 c115
78. R.N. Foley Anaemia and the heart: what's new in 2003? Nephrol Dial Transplant 18 Suppl 8 2003 13 16
79. C.T. Jurkovitz, J.L. Abramson, and L.V. Vaccarino Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study J Am Soc Nephrol 14 2003 2919 2925
80. J.L. Abramson, C.T. Jurkovitz, and V. Vaccarino Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study Kidney Int 64 2003 610 615
81. Canadian Erythropoietin Study Group Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis BMJ 300 1990 573 578
82. A.J. Collins, J.Z. Ma, and A. Xia Trends in anemia treatment with erythropoietin usage and patients outcomes Am J Kidney Dis 32 6 Suppl 4 1998 S133 S141
83. S. Sheingold, D. Churchill, and N. Muirhead The impact of recombinant human erythropoietin on medical care costs for hemodialysis patients in Canada Soc Sci Med 34 1992 983 991
84. N. Powe, R.I. Griffiths, and A.J. Watson Effect of recombinant erythropoietin on hospital admission, readmission, length of stay and costs in dialysis patients J Am Soc Nephrol 4 1994 1455 1465
85. A. Martinez-Vea, A. Bardaji, and C. Garcia Long term myocardial effects of correction of anemia with recombinant human erythropoietin in aged patients on hemodialysis Am J Kidney Dis 19 1992 353 357
86. D.A. Revicki, R.E. Brown, and D.H. Feeny Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients Am J Kidney Dis 25 1995 548 554
87. A. Besarab, W.K. Bolton, and J.K. Browne The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 339 1998 584 590
88. R.N. Foley, P.S. Parfrey, and J. Morgan Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy Kidney Int 58 2000 1325 1335
89. S.D. Roger, L.P. McMahon, and A. Clarkson Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial J Am Soc Nephrol 15 2004 148 156
90. Foley RN, Parfrey PS, Wittreich BH, et al. The effect of higher haemoglobin levels on left ventricular cavity volume in patients starting haemodialysis: a blinded, randomised, controlled trial in 596 patients without symptomatic cardiac disease [abstract]. ERA-EDTA, Lisbon, Portugal, 2004. Available at: http://abstracts 2view.com/era/authorindex.php. Accessed January 26, 2005.
91. O. Ifudu, M. Dawood, and P. Homel Excess morbidity in patients starting uremia therapy without prior care by a nephrologist Am J Kidney Dis 28 1996 841 845
92. S.J. Schwab Improving access patency: pre-end-stage renal disease strategies J Am Soc Nephrol 9 12 Suppl 1998 S124 S129